Presentation 2006, NYC Ibogaine Forum, Saturday, February 25 and Sunday , February 26 26. Saturday Forum at Lerner Hall, Columbia University. Sunday forum at Chapel of Sacred Mirrors, 540 West 27th Street.
Tabernanthe iboga being cultivated in Gabon.
Ibogaine is found in the roots of the West African Plant Tabernanthe iboga
Root scrapings are used in Bwiti initiation rites. At times a liquid extraction is used.
Bottles of purified Ibogaine hydrochloride that is used to treat chemical dependence.
Bottles of purified Ibogaine hydrochloride that is used to treat chemical dependence.
Chemical data courtesy of Merck Index.
Political action groups formed coalitions to provide Ibogaine therapy and petition governments to make it an approved drug.
As a shock tactic and to gain attention the International Coalition for Addict Self-Help chose this graphic prepared by the Amsterdam squatters movement as their logo which was emblazed on mailing envelopes to attract attention.
Adriaans was a social activist and researcher for the European Addiction Research Institute at Erasmus University Rotterdam.
Organizing in the US assumed YIPPIE tactics of street media and protest. Ibogaine banner seen during the 1991, NYC Gay Pride Parade.
Cures-Not-Wars, the YIPPIE derived anti-drug-war and AIDS activist group organized protests at the National Institute on Drug Abuse to pressure NIDA for Ibogaine research.
Ibogaine activism continues today on the internet where ibogaine is the subject of an international list with over 5,000 members of the ibogaine/Iboga community.
While this presentation was being developed (July - Nov 2004) the issues that it addressed of the rights of drug users to have access to ibogaine moved from concept and discussion to reality with the emergence of an Ibogaine underground railroad that brought Ibogaine to inner city drug users. Interview posted to drugwar.com August 26, 2004.
The medical community except under the rarest circumstances does not involve itself with the use of experimental medications. The pharmaceutical industry has chosen not to develop new drugs to treat chemical dependence due to lack of profitability, stigma attached to the patient population and greater liability attached to that population as the death rate in that population is three to seven times that of the general population. Government has chosen to develop opioid drugs rather than the newer iboga alkaloid medications as their experts are opioid medicinal chemicals and pharmacologists.
Ibogaine: Politics & Science
A History of the Science and Politics of ibogaine Howard S. Lotsof Dora Weiner Foundation Staten Island, NY @ 6th National HRC Conference Oakland, CA November 2006
Ibogaine Found in a West African plant Tabernanthe iboga
Iboga alkaloids are concentrated in the bark of the root
Usable forms include scraped or ground root bark
Physical Characteristics of ibogaine Source Merck Index Chemical formula C 20 H 26 N 2 O Mol. Wt. 310.42 Melting Point 152-153° Practically insoluble in water. Soluble in ethanol, ether, chloroform Molecular structure
Regulatory and Scientific Development The first attempt at drug development of ibogaine was by the Dora Weiner Foundation in 1983 . In 1986 , a for-profit corporation, NDA International, Inc. was established and subsequently raised 4 million towards the approval of ibogaine, initiating research and patent development. 1991 , National Institute on Drug Abuse ibogaine research project. 1993 , FDA approval for University of Miami clinical study.
Ibogaine Patents <ul><li>Rapid method for interrupting the narcotic addiction syndrome, US 4,499,096 (1985) </li></ul><ul><li>Rapid method for interrupting the cocaine and amphetamine abuse syndrome US 4,587,243 (1986) </li></ul><ul><li>Rapid method for attenuating the alcohol dependency syndrome, US 4,957,523 (1989) </li></ul><ul><li>Rapid method for interrupting or attenuating the nicotine/tobacco dependency syndrome, US 5,026,697 (1991) </li></ul><ul><li>Rapid method for interrupting or attenuating poly-drug dependency syndromes, US 5, 124,994 (1992) </li></ul>
First scientific publication of ibogaine antiaddictive effects
Additional research supports Dr. Dzoljic’s findings. Dr. Stanley D. Glick at Albany Medical College begins the publication of what will be dozens of research papers
Ibogaine effects on cocaine (Cappendijk & Dzoljic)
Ibogaine effects on alcohol (Rezvani et al. 1995)
18-methoxycoronaridine effects on methamphetamine and nicotine
18-methoxycoronaridine: No Noribogaine: No Ibogaine: Yes Approximately 4,000 patients have been treated with ibogaine. Ten fatalities have been reported within 72 hours of administration in ibogaine treated patients. Clinical use
Ibogaine science continues to grow providing 100s of peer reviewed papers
National Institute on Drug Abuse (NIDA) funds 85% of drug addiction research worldwide
NIDA Initially Rejects Ibogaine Research. NIDA was petitioned to perform ibogaine research 1984 - 1990, first by the Dora Weiner Foundation and from 1986 on by NDA International, Inc., a company established to make ibogaine available as an approved medication. In 1991, NIDA formed its Medications Development Division (MDD) and accepted a Product Profile Review (PPR) from NDA International that resulted in NIDA starting their ibogaine research program.
Ibogaine Activist Advocacy Organizations Play Role in Ibogaine Development <ul><li>International Coalition for Addict Self-Help (ICASH) 1989 </li></ul><ul><li>Dutch Addict Self-Help (DASH) 1990 </li></ul><ul><li>Cures-Not Wars (ibogaine and other issues) 1994 </li></ul><ul><li>Ibogaine Underground 2004 </li></ul>
ICASH logo Used to attract attention of government officials and media
Nico Adriaans was one of the founders of both the Rotterdam Junkies Union and Dutch Addict Self-Help (DASH). DASH was an ibogaine self-help organization that petitioned the Dutch government and organized drug users to demand ibogaine availability. DASH provided ibogaine at no cost to heroin users.
Cures-Not-Wars placed pressure on NIDA to support Ibogaine research through protests
Mindvox internet ibogaine list (user advocacy continues) <ul><li>“ We all got to help each other best we can. No one else gives a shit ‘bout us hippy freak junkies? ” </li></ul><ul><li>anon. </li></ul><ul><ul><li>To join send an email to </li></ul></ul><ul><ul><li>[email_address] </li></ul></ul>
“ FM- … We feel that continuing the focus offshore, outside the US, has not served a majority of people inside the US. Like many other grassroots movements, which facilitated change, treatments, sessions, need to be done where they belong, in all major US cities, as cost effectively as possible. “ http://www.drugwar.com/ibonyc.shtm Ibogaine underground appears 2004
Ibogaine represents both harm reduction and demand reduction DEA desk officer in the Netherlands asks how the Dutch are allowing a demand reduction drug like ibogaine to be researched in the Netherlands? Ibogaine proponents view the drug as significant harm reduction tool and basis for political action.
Stigma A mark of disgrace associated with a particular circumstance, quality or person: for instance the stigma of chemical dependence.
Ibogaine Effects on Stigma Ibogaine has the ability to remove the stigmatized condition, transforming the patient to a state often described as a preaddictive. The transformation of a stigmatized person into one who is not stigmatized will have significant affects on the individual and the society, allowing a greater contribution to self and society.
Why ibogaine is not available <ul><li>Industry deems ibogaine not to be profitable. (not a maintenance drug) </li></ul><ul><li>2. The molecule is found in nature and cannot be owned. </li></ul><ul><li>3. Stigmatized patient population with liability higher than general population due to a greater mortality rate. </li></ul><ul><li>4. Government, industry and academia chose to place their interest to treat narcotic dependence in the development of opiate drugs with which they are familiar. </li></ul><ul><li>5. Ibogaine represents a new scientific paradigm to the understanding of addiction. </li></ul><ul><li>Lack of prioritization of pharmacotherapies. </li></ul>
Failed to adequately respond to make ibogaine available <ul><li>The medical community </li></ul><ul><li>The pharmaceutical industry </li></ul><ul><li>Government </li></ul>
Paths to ibogaine availability <ul><li>Pharmaceutical company or government agency prepared to finance regulatory development. </li></ul><ul><li>Supplies of pharmaceutical grade ibogaine. </li></ul><ul><li>Grassroots constituency demanding availability of ibogaine. </li></ul><ul><li>Political advocacy movement to pressure government and industry into action. </li></ul><ul><li>A scientific community supporting ibogaine research. </li></ul>
Why ibogaine should be available <ul><li>Ibogaine significantly reduces withdrawal </li></ul><ul><li>Interrupts drug craving </li></ul><ul><li>Returning patients to a preaddictive state </li></ul><ul><li>Eliminates stigma </li></ul><ul><li>Returns free choice </li></ul>
Its in your hands now! Activism and advocacy must be renewed